Lantern Pharma Secures Patent for LP-284 from Japanese Patent Office

purple and red paper lanterns

Introduction to Lantern Pharma

Lantern Pharma, a biopharmaceutical company recognized for its innovative drug development strategies, has recently achieved a significant milestone. The company has been granted a certificate of patent from the Japanese Patent Office (JPO) for its composition of matter covering the drug candidate LP-284.

Details of the Patent

The certificate of patent from the JPO secures the intellectual property rights for Lantern Pharma’s LP-284. This patent is pivotal as it protects the unique composition of matter for LP-284, a drug candidate that holds promise in treating various forms of cancer. The patent ensures that Lantern Pharma retains exclusive rights to develop and commercialize LP-284 in Japan, a key market for pharmaceutical innovations.

Implications for Lantern Pharma

Securing this patent is a strategic victory for Lantern Pharma. It not only solidifies the company’s intellectual property portfolio but also enhances its competitive edge in the oncology drug market. The patent for LP-284 is expected to attract potential partnerships and investments, facilitating further research and development. This advancement underscores Lantern Pharma’s commitment to pioneering effective cancer treatments through cutting-edge technology and scientific research.


Lantern Pharma’s receipt of the certificate of patent from the Japanese Patent Office for LP-284 marks a noteworthy achievement in the company’s journey. This patent not only safeguards the innovative composition of LP-284 but also positions Lantern Pharma for future growth and collaboration in the global pharmaceutical landscape. As the company continues to develop LP-284, the patent will play a crucial role in its strategic endeavors and long-term success.

Discover more from Trending news

Subscribe to get the latest posts sent to your email.

Leave a Comment

Discover more from Trending news

Subscribe now to keep reading and get access to the full archive.

Continue reading